Kerrie Brady, Chief Executive Officer and President of OcuTerra Therapeutics shared updates from the company including the development of OTT166 at the 2023 ASRS annual meeting.
Kerrie Brady, BPharm, MBA, MS, Chief Executive Officer and President of OcuTerra Therapeutics spoke with our team about some updates from the company including the development of OTT166 at the 2023 ASRS annual meeting.
Editor's note - This transcript has been edited for clarity.
[I'm] Kerrie Brady, Chief Executive Officer and President of OcuTerra Therapeutics. We're an ophthalmology-focused biotech company based in Boston. [The] focus of our pipeline is developing OTT166, which is a selective integrant inhibitor, [in] which the molecule has been engineered so that it can be delivered via an eyedrop. We have very compelling Phase 1b data in patients, showing that the molecule gets to the retina and has a significant biological effect after eyedrop administration. Just last week, we announced the big news that we are fully enrolled our Phase 2 trial, the Diabetic Retinopathy: Early Active Management trial, [or] the DR:EAM study. In this study, we're testing 2 dose levels of our eyedrops OTT166 in patient population that have nonproliferative diabetic retinopathy, moderately severe to severe. Also, a portion of patients who have proliferative diabetic retinopathy but mild. All the patients do not yet have vision threatening complications, such as diabetic macular edema. The aim of the study is to determine if we can not only improve the health of the retina, but also delay or prevent progression to a vision threatening complication, which would then require some invasive treatment. The study population that we have are 225 patients. This study has been conducted entirely in the US, and we look forward to bringing you news of our topline results in the first quarter of next year. For ophthalmologists and for their patients, this means for the first time, there's a locally-acting, non-invasive treatment for those patients who are currently managed where the standard of care is active surveillance, or watch and wait. So, with a non-invasive patient administered eye drop, we can move from active surveillance to active treatment earlier in the disease process.